Dompe's Private Power
Milan's Dompé Biotec is arguably Italy's leading marketer of biotechnology products. The wholly-owned subsidiary of Dompé Farmaceutici SPA gained access to three early products of biotechnology by allying with the large multinational firms that held European rights to them. But the privately held Italian firm has since made a point of directly pursuing American biotech companies, because they have what it wants: innovative treatments for specific medical conditions. But even the most carefully considered in-licensing deals won't help Dompé grow as fast as its owners would like. The firm, now intent on expanding its reach beyond Italy, hopes its past marketing experience will attract new partners.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."